芳香化酶抑制剂治疗晚期或复发性子宫内膜癌的研究进展

doi:10.12280/gjfckx.20210580

摘要/Abstract

摘要：

近年来,子宫内膜癌复发率和死亡率呈上升趋势,严重威胁女性的生命健康。无论是子宫内膜癌术后预防复发转移的辅助治疗,还是晚期或复发转移性子宫内膜癌的治疗,内分泌治疗都占有十分重要的地位。芳香化酶抑制剂是临床中常见的辅助内分泌治疗药物,其具有强选择性,可通过抑制雌激素合成,减少雌激素对子宫内膜癌细胞的刺激,从而抑制肿瘤细胞的增殖。回顾芳香化酶抑制剂在子宫内膜癌中的临床疗效,并探讨增强芳香化酶抑制剂治疗效果的潜在策略,如联合紫杉醇+卡铂、联合新型靶向治疗药物以及二甲双胍等。

关键词: 子宫内膜肿瘤, 肿瘤复发,局部, 芳香酶, 芳香化酶抑制剂, 药物疗法,联合

Abstract:

In recent years, the recurrence rate and mortality rate of endometrial cancer are on the rise, seriously threatening women′s life and health. Endocrine therapy plays a very important role in adjuvant therapy for postoperative prevention of recurrence and metastasis of endometrial cancer, as well as in the treatment of advanced or recurrent metastatic endometrial cancer. Aromatase inhibitors are common adjuvant endocrine heraputic drugs in clinical practice. They are highly selective and can reduce the stimulation of endometrial cancer cells by inhibiting estrogen synthesis, to inhibit the proliferation of tumor cells. This article reviews the clinical efficacy of aromatase inhibitors in endometrial cancer and discusses potential strategies to enhance the efficacy of aromatase inhibitors, such as combination of paclitaxel and carboplatin, combination of novel targeted therapies, and metformin.

Key words: Endometrial neoplasms, Neoplasm recurrence,local, Aromatase, Aromatase inhibitors, Drug therapy,combination

张绍, 孔宪超. 芳香化酶抑制剂治疗晚期或复发性子宫内膜癌的研究进展[J]. 国际妇产科学杂志, 2022, 49(1): 1-4.

ZHANG Shao, KONG Xian-chao. Research Progress of Aromatase Inhibitors in the Treatment of Advanced or Recurrent Endometrial Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(1): 1-4.

参考文献 29

[1]	Lheureux S, McCourt C, Rimel BJ, et al. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report[J]. Gynecol Oncol, 2018Feb 22; S0090-8258(18)30124-0. doi: 10.1016/j.ygyno.2018.02.005. doi: 10.1016/j.ygyno.2018.02.005
[2]	谢玲玲, 林荣春, 林仲秋. 《2021 NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(1):75-81. doi: 10.19538/j.fk2021010119. doi: 10.19538/j.fk2021010119
[3]	车祺, 刘素英, 董曦. 肿瘤微环境促进子宫内膜癌细胞分泌雌激素[J]. 中国临床医学, 2020, 27(2):313-316. doi: 10.12025/j.issn.1008-6358.2020.20192041. doi: 10.12025/j.issn.1008-6358.2020.20192041
[4]	Caron-Beaudoin É, Viau R, Sanderson JT. Effects of Neonicotinoid Pesticides on Promoter-Specific Aromatase (CYP19) Expression in Hs578t Breast Cancer Cells and the Role of the VEGF Pathway[J]. Environ Health Perspect, 2018, 126(4):047014. doi: 10.1289/EHP2698. doi: 10.1289/EHP2698
[5]	陈昊, 马晓欣. 年轻早期高分化子宫内膜样腺癌患者保守治疗新进展[J]. 国际妇产科学杂志, 2018, 45(3):295-300. doi: 10.3969/j.issn.1674-1870.2018.03.015. doi: 10.3969/j.issn.1674-1870.2018.03.015
[6]	Mirfakhraee S, Chan A Jr, Ganji N, et al. Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report[J]. J Med Case Rep, 2021, 15(1):207. doi: 10.1186/s13256-021-02792-8. doi: 10.1186/s13256-021-02792-8
[7]	Bulun SE, Economos K, Miller D, et al. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors[J]. J Clin Endocrinol Metab, 1994, 79(6):1831-1834. doi: 10.1210/jcem.79.6.7989490. doi: 10.1210/jcem.79.6.7989490
[8]	Sasano H, Kaga K, Sato S, et al. Aromatase cytochrome P450 gene expression in endometrial carcinoma[J]. Br J Cancer, 1996, 74(10):1541-1544. doi: 10.1038/bjc.1996.586. doi: 10.1038/bjc.1996.586
[9]	Ke J, Shen Z, Li M, et al. Prostaglandin E2 triggers cytochrome P450 17α hydroxylase overexpression via signal transducer and activator of transcription 3 phosphorylation and promotes invasion in endometrial cancer[J]. Oncol Lett, 2018, 16(4):4577-4585. doi: 10.3892/ol.2018.9165. doi: 10.3892/ol.2018.9165
[10]	El-Kersh DM, Ezzat SM, Salama MM, et al. Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer[J]. Sci Rep, 2021, 11(1):7121. doi: 10.1038/s41598-021-86599-z. doi: 10.1038/s41598-021-86599-z pmid: 33782546
[11]	孟春艳, 张付菊, 苏永平. 来曲唑在乳腺癌辅助内分泌治疗中的研究进展[J]. 癌症进展, 2021, 19(5):438-441. doi: 10.11877/j.issn.1672-1535.2021.19.05.02. doi: 10.11877/j.issn.1672-1535.2021.19.05.02
[12]	Bellone S, Shah HR, McKenney JK, et al. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole[J]. Am J Obstet Gynecol, 2008, 199(3):e7-e10.
[13]	吴司韵, 苏圆圆, 张莘, 等. 来曲唑治疗子宫内膜癌的实验研究[J]. 中国妇幼保健, 2011, 26(13):1963-1966.
[14]	曾禄贤, 毛邱娴, 李文娟, 等. 芳香化酶抑制剂对人子宫内膜癌裸鼠移植瘤的抑制作用[J]. 现代医院, 2016, 16(2):167-169. doi: 10.3969/j.issn.1671-332X.2016.02.004. doi: 10.3969/j.issn.1671-332X.2016.02.004
[15]	Thangavelu A, Hewitt MJ, Quinton ND, et al. Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study[J]. Gynecol Oncol, 2013, 131(3):613-618. doi: 10.1016/j.ygyno.2013.09.023. doi: 10.1016/j.ygyno.2013.09.023 pmid: 24076063
[16]	Lindemann K, Malander S, Christensen RD, et al. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)[J]. BMC Cancer, 2014, 14:68. doi: 10.1186/1471-2407-14-68. doi: 10.1186/1471-2407-14-68 pmid: 24498853
[17]	冯艳, 师晓艳, 冯蓓, 等. 来曲唑片联合放疗对耐药性子宫内膜癌患者血清VEGF,IL-6及肿瘤标志物水平的影响[J]. 现代生物医学进展, 2017, 17(20):3913-3916. doi: 10.13241/j.cnki.pmb.2017.20.026. doi: 10.13241/j.cnki.pmb.2017.20.026
[18]	Zhang G, Cheng Y, Zhang Q, et al. ATX-LPA axis facilitates estrogen-induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway[J]. Mol Med Rep, 2018, 17(3):4245-4252. doi: 10.3892/mmr.2018.8392. doi: 10.3892/mmr.2018.8392 pmid: 29328374
[19]	Ramos J, Das J, Felty Q, et al. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways[J]. Breast Cancer Res Treat, 2018, 172(2):469-485. doi: 10.1007/s10549-018-4905-9. doi: 10.1007/s10549-018-4905-9
[20]	Barra F, Evangelisti G, Ferro Desideri L, et al. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer[J]. Expert Opin Investig Drugs, 2019, 28(2):131-142. doi: 10.1080/13543784.2018.1558202. doi: 10.1080/13543784.2018.1558202
[21]	Wheler JJ, Moulder SL, Naing A, et al. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway[J]. Oncotarget, 2014, 5(10):3029-3038. doi: 10.18632/oncotarget.1799. doi: 10.18632/oncotarget.1799
[22]	Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma[J]. J Clin Oncol, 2015, 33(8):930-936. doi: 10.1200/JCO.2014.58.3401. doi: 10.1200/JCO.2014.58.3401 pmid: 25624430
[23]	周瑜辉, 王彬, 牛利刚, 等. 二甲双胍调节miR-26a-5p表达对乳腺癌MCF7细胞的影响[J]. 医学分子生物学杂志, 2019, 16(6):512-517. doi: 10.3870/j.issn.1672-8009.2019.06.005. doi: 10.3870/j.issn.1672-8009.2019.06.005
[24]	Bateman NW, Teng PN, Hope E, et al. Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers[J]. Cancer Med, 2020, 9(3):1092-1103. doi: 10.1002/cam4.2729. doi: 10.1002/cam4.2729
[25]	Bahrambeigi S, Shafiei-Irannejad V. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin[J]. Biochem Pharmacol, 2020, 174:113787. doi: 10.1016/j.bcp.2019.113787. doi: S0006-2952(19)30486-1 pmid: 31884044
[26]	Soliman PT, Westin SN, Iglesias DA, et al. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study[J]. Clin Cancer Res, 2020, 26(3):581-587. doi: 10.1158/1078-0432.CCR-19-0471. doi: 10.1158/1078-0432.CCR-19-0471 pmid: 31628143
[27]	王学慧, 柳春韬, 包洪丽, 等. 来曲唑联合紫杉醇卡铂治疗复发性子宫内膜癌的临床观察[J]. 中国现代医生, 2019, 57(28):63-67. doi: CNKI:SUN:ZDYS.0.2019-28-018. doi: CNKI:SUN:ZDYS.0.2019-28-018
[28]	Liu Y, Wang LL, Chen S, et al. LncRNA ABHD11-AS1 promotes the development of endometrial carcinoma by targeting cyclin D1[J]. J Cell Mol Med, 2018, 22(8):3955-3964. doi: 10.1111/jcmm.13675. doi: 10.1111/jcmm.13675
[29]	Hu J, Shen J, Sun J. CDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer[J]. Biomed Pharmacother, 2020, 125:109870. doi: 10.1016/j.biopha.2020.109870. doi: 10.1016/j.biopha.2020.109870